

[Open Peer Review on Qeios](#)

Bevacizumab

National Cancer Institute

Source

National Cancer Institute. *Bevacizumab*. NCI Thesaurus. Code C2039.

A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.